NL-OMON41230CompletedNot Applicable
A Phase 2 study for older adults with Acute Lymphoblastic Leukaemia - UKALL60+/HO117 A
Cancer Research UK & UCL Cancer Trials Centre0 sites48 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 48
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Age >= 60 with Acute Lymphoblastic Leukaemia (ALL) OR >= 55 with Acute Lymphoblastic Leukaemia (ALL) unsuitable for the UKALL14 or HOVON 100 trial
- •Newly diagnosed, previously untreated ALL (a steroid pre-phase of 5-7 days may be given before study registration)
- •Written informed consent
Exclusion Criteria
- •Known HIV infection
- •Blast transformation of CML
- •Mature B-cell leukemia i.e. Burkitt*s disease t(8,14)(q24;q32) and variant c-myc translocations e.g. t(2;8)(p12;q24),t(8;22)(q24;q11)
- •Women who are pregnant or lactating
Investigators
Similar Trials
Active, not recruiting
Phase 1
The AML18 Trial is an intensive chemotherapy trial for patients primarily over the age of 60 with AML and High Risk Myelodysplastic disease. This randomised, up to 2000 patient trial will evaluate the effect of adding novel treatment combinations to standard chemotherapy.Acute Myeloid LeukaemiaHigh Risk Myelodysplastic SyndromeMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-002730-21-GBCardiff University2,000
Active, not recruiting
Phase 1
The AML18 Trial is an intensive chemotherapy trial for patients primarily over the age of 60 with AML and High Risk Myelodysplastic disease. This randomised, up to 2000 patient trial will evaluate the effect of adding novel treatment combinations to standard chemotherapy.Acute Myeloid LeukaemiaHigh Risk Myelodysplastic SyndromeMedDRA version: 20.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersEUCTR2013-002730-21-DKCardiff University2,000
Active, not recruiting
Not Applicable
A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior to hematopoietic stem cell transplantation. - NDAdults with acute myelogenous leukaemia (AML) in first complete remission (CR1)MedDRA version: 9.1Level: PTClassification code 10000881EUCTR2009-016601-42-ITPierre Fabre Medicament28
Active, not recruiting
Phase 1
A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior to hematopoietic stem cell transplantation.Acute myeloid leukaemiaMedDRA version: 12.1Level: PTClassification code 10000881Term: <Manually entered code. Term in E.1.1>EUCTR2009-016601-42-FRPIERRE FABRE MEDICAMENT30
Completed
Phase 2
A Phase II study in adult patients with newly-diagnosed chronic myeloid leukaemia of initial intensified Glivec® therapy, and sequential combination therapy for non-responders. With Protocol Amendments October 2004: to include an Extension Phase of the StudyACTRN12607000614493Australasian Leukaemia and Lymphoma Group103